Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01160614 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients
A Phase 1 study of Opioid Analgesia, sponsored by Purdue Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 17
- Study locations
NCT01160614 is a Phase 1 study of Opioid Analgesia that has completed, run by Purdue Pharma. The registered enrollment target is 30 participants. The trial reports 17 study locations across 13 states.
The verdict
NCT01160614, a Phase 1 study of Opioid Analgesia, has completed, sponsored by Purdue Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to characterize the pharmacokinetics (PK) of single-dose ORF tablets in pediatric patients aged 6 to 16 years, inclusive.
Conditions Studied
Interventions
- DRUG Oxycodone hydrochloride controlled-release (ORF) tablets
Study Locations (17)
Other
- The Royal Children's Hospital - Parkville
- Helsinki University Central Hospital/Children and Adolescent Hospital - Helsinki
- Kuopio University Hospital/Operative Services and Intensive Care - Kuopio
- Waikato Clinical Research (2008) Ltd - Hamilton
Texas
- Children's Med Center of Dallas - Dallas
- Scott & White Memorial Hospital & Clinic - Temple
Arizona
- Maricopa Medical Center - Phoenix
Arkansas
- Arkansas Childrens Hospital - Little Rock
California
- LS Packard Children's Hospital - Palo Alto
Colorado
- The Children's Hospital Association - Aurora
Florida
- Research Facility - Miami
Michigan
- F3900 C.S. Mott Children's Hospital - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01160614
The ClinicalTrials.gov registry entry for NCT01160614 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purdue Pharma, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid Analgesia appearing as the primary indexed condition, and to 1 intervention - of which Oxycodone hydrochloride controlled-release (ORF) tablets is the first listed.
NCT01160614 reports 17 study locations spanning 13 distinct geographic areas - top geographies include Other, Texas, Arizona.
Frequently Asked Questions
What is clinical trial NCT01160614 about?
NCT01160614 is a clinical study titled "Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients". The purpose of this study is to characterize the pharmacokinetics (PK) of single-dose ORF tablets in pediatric patients aged 6 to 16 years, inclusive.
What is the current status of trial NCT01160614?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2010-07. Estimated completion is 2011-08.
What conditions does trial NCT01160614 study?
This clinical trial studies the following conditions: Opioid Analgesia.
What interventions are being tested in trial NCT01160614?
The interventions under investigation include: Oxycodone hydrochloride controlled-release (ORF) tablets (DRUG).
Who is sponsoring clinical trial NCT01160614?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01160614 being conducted?
This trial has 17 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Analgesia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.